FLT3 and acute myeloid leukemia: First, Gallipoli, et al. 30 have performed a genome-wide CRISPR/Cas9 screen using FLT3 inhibitor AC220 to select genes and pathways that would sensitize FLT3-ITD AML to FLT3-TKI treatment, which provide us a perfect source (GSE105161) to study the connection between drug response and aerobic glycolysis.